Virpax Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OTC.Pink
DEF 14A: Virpax Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split and Director Elections
Virpax Pharmaceuticals is holding a special meeting to seek stockholder approval for a reverse stock split and the election of five directors.
OTC.Pink
DEFA14A: Virpax Pharmaceuticals Announces Board Reconfiguration and Director Nominees Ahead of Annual Meeting
Virpax Pharmaceuticals supplements its proxy statement to announce board changes, including director resignations and appointments, and updates director nominees for the upcoming annual meeting on July 29, 2024.
OTC.Pink
Virpax Pharmaceuticals is asking stockholders to approve amendments to its 2022 Equity Incentive Plan, including increasing the number of shares available for issuance and the evergreen provision percentage, at its upcoming annual meeting.